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Abstract
Sarcoidosis is an inflammatory disease of unknown etiology. Most commonly it results in the formation of non-caseating granulo-
mas in intrathoracic lymph nodes and lung parenchyma, but the clinical course and picture may be complicated by extrapulmonary 
involvement and many non-respiratory signs and symptoms which are directly related to the disease. In addition, sarcoidosis 
patients may suffer from a plethora of symptoms of uncertain or unknown origin. Fatigue is one of these symptoms, and according 
to some authors it is reported by the majority of patients with active sarcoidosis, but also by a smaller proportion of patients with 
inactive sarcoidosis, or even with complete clinical and radiological remission. Therefore the term fatigue syndrome is frequently 
used to name this clinical problem. The definition of fatigue syndrome in sarcoidosis is imprecise and the syndrome is usually 
recognized by use of validated questionnaires. In this review the uptodate knowledge in this field was presented and different 
challenges connected with this syndrome were described.
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Introduction
Sarcoidosis is a multisystemic disease of 
unknown etiology, characterized by formation 
of non-caseating granulomas in different organs. 
Most frequently the disease presents with en-
larged intrathoracic lymph nodes and/or lung 
parenchymal infiltrations. It has been estimated 
to be the second frequent chronic respiratory di-
sease among young adults (< 40 year of life), after 
asthma. Prevalence may be different in different 
ethnic groups, and is estimated to 5−40/100,000. 
In some European countries (ie Denmark) its in-
cidence is close to 5/100,000/year [1−4].
Extrathoracic manifestations can result either 
from direct organ involvement (most frequently 
skin, peripheral lymph nodes, eyes, liver, spleen, 
but all organs may be involved). Many general 
or non-respiratory symptoms may be unrelated 
to specific organ involvement. For instance, 
patients with altered vitamin D metabolism and 
hypercalciuria may suffer from nephrolithiasis 
or symptoms related to high serum calcium con-
centration. The plethora of non-specific general 
or non-respiratory symptoms unrelated to specific 
organ involvement include fever, weight loss, 
myalgia, arthralgia, sweating, general malaise, 
depression, and fatigue. The origin and etiology 
of these symptoms is largely unknown. 
Chronic fatigue is one of the symptoms most 
frequently reported by sarcoidosis patients. 
Interestingly, it may appear both in the course 
of active sarcoidosis as well as in those with 
disease remission. Its frequency is estimated at 
50−70% of all sarcoidosis patients [2, 5, 6]. It 
is associated with decreased quality of life and 
quite often with depression [5−7]. In 1994 Ame-
rican Centers for Disease Control and Prevention 
(CDC) defined chronic fatigue syndrome (CFS) 
as a “debilitating and complex disorder characte-
rized by intense fatigue that is not improved by 
bed rest and that may be worsened by physical 
activity or mental exertion. People with CFS 
often function at a substantially lower level of 
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activity than they were capable of before they 
became ill” [8]. 
The document further precise, that the dia-
gnosis requires three criteria:
1) The individual has had severe chronic fatigue 
for 6 or more consecutive months that is not 
due to ongoing exertion or other medical con-
ditions associated with fatigue (these other 
conditions need to be ruled out);
2) The fatigue significantly interferes with daily 
activities and work;
3) The individual concurrently has 4 or more 
of the following 8 symptoms:
 — post-exertion malaise lasting more than 
24 hours,
 — unrefreshing sleep,
 — significant impairment of short-term 
memory or concentration, 
 — muscle pain,
 — pain in the joints without swelling or 
redness,
 — headaches of a new type, pattern, or 
severity,
 — tender lymph nodes in the neck or armpit,
 — a sore throat that is frequent or recurring.
These symptoms should have persisted or 
recurred during 6 or more consecutive months 
of an illness and they cannot have first appeared 
before the fatigue [cited from 8]. 
These criteria describe fatigue syndrome, 
regardless the reason. The syndrome has been de-
scribed in a variety of different clinical contexts, 
for instance in patients infected with various 
viruses (Ebstein-Bar, human immunodeficiency 
virus, hepatitis C), neoplastic disease, rheuma-
toid arthritis and systemic sclerosis, multiple 
sclerosis, fibromyalgia, obstructive sleep apnea 
and many others [8, 9].
Types of fatigue in sarcoidosis patients
Sharma [10] depicted four types of fatigue in 
patients with sarcoidosis:
1)  Early-morning fatigue — when the patient is 
not able to arise or arises with the feeling of 
inadequate sleep;
2)  Intermittent fatigue — when the patient wakes 
up in good condition and feeling of adequate 
sleep rest, but after few hours of daytime ac-
tivity become tired and exhausted. After an 
hour or more is able to restart his/her activity;
3)  Afternoon fatigue — the patient wakes up 
refreshed and full of energy, but in the early 
afternoon feels exhausted, and this feeling 
continues until next morning; 
4) Post-sarcoidosis chronic fatigue syndrome — 
which occurs in patients who are evidently 
free of disease, with clinical and radiological 
signs of remission.
De Kleijn et al. [11] examined 434 patients 
with chronic sarcoidosis, and divided the whole 
cohort into three groups:
1) Mild fatigue — patients with no fatigue or with 
only mild symptoms;
2) Intermittent fatigue — described in a similar 
way as by Sharma [10];
3) All-day fatigue — when the feeling of fatigue 
is constant and lasts the whole day.
Because the authors have not found patients 
with remission of sarcoidosis in their study group 
(only active sarcoidosis patients were included), 
they could not confirm the presence of post-sar-
coidosis fatigue syndrome. They also have not 
found any patients matching to afternoon fatigue 
type described by Sharma [10]. In our practice the 
post-sarcoidosis fatigue syndrome happens quite 
frequently. It is a real challenge for researchers 
and practitioners, as the definition and criteria 
are even more vague, than in case of fatigue as-
sociated with any other active chronic disease. 
Sharma estimated that it occurs in about 5% of 
sarcoidosis patients [10].
Different measures to estimate fatigue
In face of a variety of different types of fatigue 
and a long list of chronic diseases and states, that 
can be accompanied by fatigue, many different qu-
estionnaires have been used for fatigue assessment 
[9]. Questionnaires have the advantage over the 
simple yes-or-no response to the question asked to 
the patient about the feeling of fatigue, and allow 
objective assessment of fatigue severity. In fact, 
other objective tests are unknown, therefore the 
diagnosis of fatigue syndrome needs to be based 
on questionnaires, with an estimated threshold 
cut-off value which is believed to differentiate 
those suffering from clinically significant fatigue 
form fatigue-free individuals. Many of them have 
been tried also in sarcoidosis. The only validated 
method of its evaluation in this special group of 
patients is Fatigue Assessment Scale (FAS) [12]. 
This scale consists of 10 questions specific for 
sarcoidosis-related fatigue, five of them describing 
physical and five — mental fatigue (Table 1). A 
value of 22 and above points has been set up to 
discriminate patients with from those without si-
gnificant fatigue [12]. It has been shown in various 
clinical contexts, that FAS is an unidimentional 
instrument (describes fatigue quantitatively and 
Pneumonologia i Alergologia Polska 2016, vol. 84, no. 4, pages 244–250 
246 www.pneumonologia.viamedica.pl
independently of other confounders, such as de-
pression) [13, 14]. This feature was also confirmed 
in a population of sarcoidosis patients [12]. The 
change of 4 points in a certain time is considered 
a minimal clinically important difference [15]. In 
fact, FAS is the most important method to diagnose 
fatigue and to estimate its severity.
Other scales used for the multidimentional 
assessment of sarcoidosis-related fatigue include: 
WHOQOL-100 — World Health Organization 
Quality of Life Assessment Instrument-100 [12], 
MFI — Multidimentional Fatigue Inventory [16], 
FACIT-F — Functional Assessment of the Chronic 
Illness Therapy-Fatigue [17], SHQ — Sarcoidosis 
Health Questionnaire, SF-36 [18], CRDQ — Chron-
ic Respiratory Disease Questionnaire [12]. BDI — 
Beck Depression Inventory score [12] may be used 
for the assessment of accompanying depression, 
and may be helpful in differentiating fatigue from 
depression-related symptoms. Borg Scale and MRC 
— Medical Research Council scale may be used 
for the assessment of dyspnea and exercise intol-
erance, which frequently accompany fatigue [19]. 
Possible causes of fatigue in sarcoidosis
Factors responsible for fatigue in patients 
with sarcoidosis has not been defined. It is presu-
med, that the etiology is multifactorial and related 
not only to chronic systemic inflammation but 
also to other factors, for instance to comorbidities, 
treatment and psychological factors.
Inflammation
In early active phase of sarcoidosis the CD4 
lymphocytes predominance is observed, and lym-
phocytes differentiate to Th1 immunophenotype, 
which is characterized by production of specific 
cytokines, such as interleukin (IL)-2 and interfer-
on (INF)-g. Activated macrophages produce — in 
response to these cytokines — large amounts of tu-
mor necrosis factor (TNF)-a. During recovery the 
balance between Th1 and Th2 immunophenotypes 
reverses. Interestingly, in patients with post-sar-
coidosis fatigue syndrome, Korenromp et al. 
[20] observed decreased production of Th2- 
-related cytokines (IL-4, IL-5, IL-10) and decreased 
concentration of monocyte chemotactic protein 
(MCP)-1, also referred to as chemokine (C-C 
motif) ligand 2 (CCL2), which is responsible for 
activation of Th2 lymphocytes. Increased Th2 
response in sarcoidosis remission is supposed to 
„calm-down” the inflammatory reaction. There-
fore, inadequate Th1 to Th2 re-shifting may 
contribute to fatigue in these patients. The same 
authors in a separate study found lower ACTH 
and cortisol serum concentrations in patients 
with post-sarcoidosis fatigue than patients in re-
mission who do not report fatigue [21]. They also 
reported on the specific personality profile with 
profound neurotic characteristics in combination 
with high levels of psychological distress [21]. 
The authors propose, that these findings should 
be taken into account when different treatment 
options are considered. Baydur et al. [22] studied 
relations between fatigue and baseline (resting) 
and post-exercise serum levels of TNF-a and IL-1b 
in sarcoidosis patients comparing to healthy con-
trols. They found that patients exhibited greater 
fatigue, reduced cardiopulmonary function, high-
er MRC dyspnea scores and higher TNF-a plasma 
levels at all time-points. In treated patients only, 
pre-exercise plasma IL-1b correlated with physi-
cal fatigue, reduced motivation and total fatigue, 
and TNF-a levels correlated with general fatigue 
score. The authors do not answer, whether these 
findings were related to the treatment or to sub-
clinical inflammation related to the mere disease 
[22]. Inflammation is however, an unlikely reason 
of fatigue in patients with sarcoidosis remission.
Muscle weakness
Muscle weakness is a frequent complaint in 
patients suffering from sarcoidosis [23]. Study 
performed among sarcoidosis patients showed, 
that quadriceps muscle strength and handgrip 
force were not decreased, but most of these pa-
tients did not complain on fatigue [24]. In many 
studies on patients with active sarcoidosis howe-
ver, fatigue was associated with reduced muscle 
strength and exercise intolerance [25, 26]. There 
Table 1.  Questions composing the Fatigue Assessment 
Scale (FAS). Each question is evaluated in  
a 5-point scale: never — 1; sometimes — 2;  
regularly — 3; often — 4; always — 5
1. I am bothered by fatigue
2. I get tired very quickly
3. I don’t do much during the day
4. I have enough energy for everyday life
5. Physically, I feel exhausted
6. I have problems to start things
7. I have problems to start things
8. I feel no desire to do anything
9. Mentally, I feel exhausted
10. When am doing something, I can concentrate quite well
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can be few possible causes of muscle weakness 
in patients suffering from sarcoidosis, starting 
from formation of granulomas in skeletal muscles, 
through steroid myopathy, and increased levels 
of inflammatory cytokines, to decreased physical 
condition related to chronicity of the disease. It 
is of note, that muscle sarcoidosis (granulomas 
found at muscle biopsy) is a rarity. Regardless 
the reason, the link between muscle weakness 
and fatigue in sarcoidosis patients still remains 
undefined.
Lung function impairment
Fatigue itself may negatively impact exercise 
tolerance. On the other hand, the influence of 
functional impairment on the occurrence and se-
verity of fatigue have been assessed in few trials. 
Zieleźnik et al. [19] examined 76 patients with 
inactive sarcoidosis, and fatigue was reported by 
50% of them, with almost 7% reporting severe 
fatigue. The authors found weak correlation be-
tween fatigue and female gender and older age, 
but did not find any correlation between fatigue 
and spirometry parameters and the distance in 
6-minutes walking test. 
Psychological aspects 
Sarcoidosis, as a chronic disease of un-
certain long term prognosis may influence the 
psychological aspects of patient’s life, leading 
to depression and decreased quality of life. 
Chang et al. [27] reported depression in 60% of 
sarcoidosis patients, and showed correlations 
with female gender, economical status, access to 
health service and disease severity. Goracci et al. 
[28] confirmed strong relationship between sar-
coidosis and depression, and its negative impact 
on quality of life. De Klejn et al. [29] found, that 
fatigue is related to depression in 34−36% and to 
anxiety in 43−46% of patients. Similarly, Holas 
et al. reported on depression in 29% and anxiety 
in 31% of patients with active sarcoidosis [30]. 
Patients presenting all-day fatigue reported more 
symptoms linked to depression. The study also 
showed, that fatigue is frequently reported by 
patients who do not have depression at all. In few 
studies it was also shown, that depression nega-
tively impacts fatigue [31, 32]. It seems probable, 
that depression and fatigue are strictly related to 
each other. Depression may increase the feeling 
of fatigue, general reluctance to effort, aversion 
to treatment and regular medical check-ups, and 
may worsen the cooperation between the patient 
and his doctor. All these may lead to inadequ-
ate control of the disease. Sarcoidosis itself, as 
a chronic disease frequently severely complicated 
and with unpredictable prognosis may worsen 
depressive symptoms. 
The influence of treatment, comorbidities 
and extrapulmonary locations
Fleisher et al. in the German study [33] of 
over 1000 patients with sarcoidosis proved the 
influence of several different factors on the sever-
ity of fatigue. They reported, that patients with 
muscle, bone and neural involvement presented 
more severe fatigue than patients with pulmonary 
sarcoidosis. In general, patients with extrapulmo-
nary sarcoidosis have more severe fatigue than 
patients with isolated pulmonary sarcoidosis. In 
addition, the authors showed, that treatment with 
systemic steroids and methotrexate is correlated 
with more severe fatigue. There was a strong 
correlation between fatigue and comorbidities, 
such as systemic hypertension, thyroid diseases, 
obesity, restless legs syndrome, and diabetes. 
But the most strongly associated comorbidities 
with fatigue were pulmonary hypertension and 
sleep apnoe syndrome. Sleep apnoe syndrome 
is several times more frequent in patients with 
sarcoidosis than in healthy population, and may 
lead to fatigue, anxiety and depression [34, 35]. 
Many patients with sarcoidosis suffer from 
small fiber neuropathy (SFN), which affects small 
peripheral nerve fibers and manifests as severe 
hyperaesthesia, pain, numbness of distal parts 
of extremities and is associated with autonomic 
dysfunction. TNF-a may be a crucial cytokine in 
the pathogenesis of SFN [36]. Dysautonomias are 
frequently associated with chronic fatigue [37]. 
Therefore it may be presumed, that treatment of 
sarcoidosis patients suffering from chronic fa-
tigue with anti-TNF-a agents [38] or intravenous 
immunoglobulin [39] may be effective not only 
to alleviate symptoms of neuropathy, but also to 
cure fatigue.
Attempts of therapy
There is no single therapy for chronic fatigue 
syndrome in the course of sarcoidosis verified and 
evaluated in randomized trials. Although some 
authors, based on their personal experience and 
confidence suggested to treat these patients with 
low-dose systemic steroids and/or hydroxychlo-
rochine [10], there are no evidence-based data to 
prove the efficiency of this regimen. From other 
sources we can learn, that treatment with steroids 
[12] and immunosuppressive drugs [40] may be 
a causative factor of fatigue. Therefore, it seems 
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reasonable to advise to follow the general rules 
which define indications to systemic therapy in 
sarcoidosis [1]. According to these rules, fatigue 
is not an indication for systemic steroids and 
immunosuppressive drugs.
Due to multifactorial etiology and complex 
pathogenesis no single method of treatment 
exists. The majority of trials performed in the 
indication of fatigue in a plethora of different 
clinical backgrounds concerned neurostimulants 
and anti-TNF therapy [41−44]. 
Metylfenidate represents a group of drugs 
called neurostimulants, and is used in the treat-
ment of attention deficit, hyperactivity disorder 
(ADHD), and narcolepsy. It has been also used 
as an adjunctive therapy of depression [45, 46]. 
Another neurostimulant, modafinil is a dopamine 
re-uptake inhibitor used in the treatment of nar-
colepsy. Modafinil or its R isomere, armodafinil 
has been used to treat excessive sleepness in the 
course of sleep apnea syndrome [47, 48], and 
narcolepsy [49]. The drug has been also used to 
treat fatigue associated with depression [50] and 
multiple sclerosis [51, 52].
There are only few completed trials in sar-
coidosis-related chronic fatigue syndrome. Wag-
ner et al. [53], in an open-label study treated five 
patients with sarcoidosis who presented chronic 
fatigue with methylphenidate (MPH), and the 
treatment was effective in four of them. In another 
study dexmethylphenidate (d-MPH) was used to 
treat fatigue in a double-blind randomized, place-
bo-controlled, cross-over trial. The study includ-
ed 10 patients with severe sarcoidosis, all patients 
were receiving systemic therapy. The drug was 
well tolerated and substantial improvement of 
fatigue was noticed in all treated patients [54]. It 
is not clear what is the exact mechanism of this 
positive drug effect. It cannot be excluded, that 
it is connected with its antidepressive activity.
Armodafinil was used in one doble-blind, 
placebo-controlled, cross-over study [55]. The 
authors recruited 15 patients with sarcoidosis-re-
lated fatigue, in whom sleep apnea was excluded. 
The treatment significantly reduced fatigue scores 
assessed by FAS and FACIT-F questionnaires, even 
in patients who did not have excessive daytime 
somnolence. 
All these studies were performed in small 
study groups, which is an obvious limitation. 
However, the results are promising and should 
encourage researchers to design a big multina-
tional trial in order to confirm the effectiveness 
of neurostimulants in the treatment of sarcoid-
osis-related fatigue. 
TNF-a is a key cytokine in the pathogenesis 
of sarcoid inflammation, and anti-TNF drugs 
are accepted in the treatment of refractory and 
difficult-to-treat sarcoidosis [56, 57]. Chronic 
persisted inflammation may play a role in the 
pathogenesis of fatigue in sarcoidosis [58]. Data 
on the influence of anti-TNF therapy on sarcoid-
osis-related fatigue are scarce. Elfferich et al. [59] 
observed prospectively 343 patients with sarcoid-
osis, some of them with indications for systemic 
therapy (steroids, methotrexate, anti-TNF). They 
registered the cognitive impairment and fatigue at 
baseline and after 6 months follow-up, and they 
found, that only patients treated with anti-TNF 
drugs showed substantial improvement of cogni-
tion and fatigue. 
There is no doubt, that the treatment of fati-
gue related to sarcoidosis should be multidisci-
plinary. The proper therapy adjusted to clinical 
presentation, disease phenotype and severity sho-
uld be introduced in selected patients in order to 
alleviate symptoms and prevent disease progres-
sion. Treatment of comorbidities, psychotherapy, 
physical exercises and rehabilitation seems to be 
equally important.
Summary 
Chronic fatigue is a very frequent symptom 
reported by sarcoidosis patients. It may affect 
up to 70% of patients. Due to its severity and 
diurnal profile several types of fatigue have been 
described, starting from mild intermittent to 
constant fatigue. The most intriguing is the occur-
Figure 1. Possible factors involved in the pathogenesis of fatigue in 
sarcoidosis
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rence of fatigue in some patients with sarcoidosis 
remission. Chronic fatigue negatively impacts 
patient’s quality of life, increases depression and 
anxiety. The etiology remains unknown, but it has 
been postulated to occur more frequently in those 
with sustained systemic inflammation, decreased 
muscle strength, extrapulmonary presentations, 
treated with steroids and immunosuppressive 
drugs, with comorbidities and coexistent depres-
sion (Fig. 1). Effective treatment is unknown, 
however neurostimulants and anti-TNF agents 
have been shown effective in small preliminary 
trials. Psychotherapy and rehabilitation may 
be also important, however they have not been 
studied in this clinical context. Further trials of 
improved quality, involving higher numbers of 
patients and designed specifically for sarcoid-
osis-related fatigue should be planned.
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